- Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering
- Robust and sustainable treatment effects support at least bi-annual dosing regimen
- Best-in-class potential of novel PCSK9 siRNA RN0191 supports further development as single agent or combination to further reduce atherosclerosis cardiovascular risk
SHANGHAI, Nov. 18, 2024 /PRNewswire/ — Rona Therapeutics, a leader in innovative RNA-based therapies, today presented positive results from the Phase 1 clinical trial of RN0191 at the American Heart Association’s (AHA) Annual Scientific Sessions in Chicago, IL, November 16th, 2024. RN0191 is a proprietary GalNAc conjugated PCSK9 siRNA designed to significantly lower low-density lipoprotein cholesterol (LDL-C) and other lipid parameters.
The Ph1 study was a randomized, single-dose ascending, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects with elevated LDL-C. The demographics included adults aged 18 to 60 years, spanning a BMI range of 19-30 kg/m2. All results are based on data in the database as of Oct. 14, 2024. A total of 32 subjects were randomized and treated with RN0191 from 60mg to 600mg, respectively. The baseline LDL-C mean level was ranging from 110-130 mg/dL.
After a single-dose subcutaneous injection, RN0191 showed a favorable safety profile with no serious adverse events and only mild, transient adverse events reported across all dose- levels. Dose-dependent, significant and durable changes in PCSK9, LDL-C and other lipid parameters were observed (see table below).
- Mean maximum reduction of PCSK9 >85% and LDL-C >55% have been achieved. Significant and durable LDL-C reduction is achieved up to 42% through Day180, supporting a bi-annual dosing regimen for future development
- Significant lowering of ApoB, Lp(a), non-HDL-C and total cholesterol are also noted
- Remarkable treatment effects with reduction of PCSK9, LDL-C and the other lipid parameters maintained to 6 months.
|
Table. Percentage change from baseline of PCSK9 and LDL-C level after single dose of RN0191 |
|||||
|
Placebo |
60mg |
200mg |
400mg |
600mg |
|
|
PCSK9 |
|||||
|
Mean Maximum Change (%) |
-10 % |
-64 % |
-79 % |
-86 % |
-87 % |
|
(Days post injection) |
(8) |
(15) |
(29) |
(22) |
(57) |
|
Mean Change (%), Day 85 |
-4 % |
-33 % |
-69 % |
-79 % |
-83 % |
|
Individual Maximum Change (%) |
-50 % |
-81 % |
-87 % |
-91 % |
-95 % |
|
LDL-C |
|||||
|
Mean Maximum Change (%) |
-6 % |
-23 % |
-48 % |
-56 % |
-51 % |
|
(Days post injection) |
(85) |
(57) |
(29) |
(71) |
(22) |
|
Mean Change (%), Day 85 |
-6 % |
-20 % |
-36 % |
-47 % |
-45 % |
|
Individual Maximum Change (%) |
-20 % |
-63 % |
-61 % |
-71 % |
-74 % |
Stella Shi, CEO of Rona Therapeutics, shared, “We are thrilled to report that RN0191 has demonstrated best-in-class PCSK9 siRNA potential. These results highlight RN0191’s potential as a transformative siRNA therapy for global patients with elevated LDL-C, a major risk factor for atherosclerotic cardiovascular disease either as single agent therapy or as combinatory backbone to improve cardiovascular outcome. “
About Rona Therapeutics
Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH. In addition, Rona Therapeutics is unlocking potential of extra-hepatic delivery for neurological disorders and adipose/muscle delivery or various metabolic syndromes.
For Further information,
Please visit: www.ronatherapeutics.com or contact: BD@ronatherapeutics.com
The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Business Directory.